FDMT
Neutral signalScored 2026-09-18 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
4D Molecular Therapeutics, Inc.
- Nom
- 4D Molecular Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $596.6M
- Employés
- 196
- PDG
- David H. Kirn
- Site web
- https://www.4dmoleculartherapeutics.com
- Marché
- ABEOLXEOMGTXOCGNQURERGNX
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 116 666 titres (~1 564 753,56 $ US)
- Insiders
- Kirn David
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,730,730
Avg sell (VWAP, 90d window) $13.22 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,709,736 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-05
- Last synced
-
2026-10-11 09:55:21
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-16 | Bizily Scott | Sell · S | 1,635 | $12.84 | $20,993 | Form 4 |
| 2026-10-05 | Kirn David | Sell · S · 10b5-1 | 272 | $13.61 | $3,702 | Form 4 |
| 2026-09-16 | Bizily Scott | Sell · S · 10b5-1 | 1,635 | $13.65 | $22,318 | Form 4 |
| 2026-09-14 | Kirn David | Sell · S · 10b5-1 | 58,333 | $13.90 | $811,004 | Form 4 |
| 2026-09-01 | Bizily Scott | Sell · S · 10b5-1 | 584 | $14.00 | $8,176 | Form 4 |
| 2026-08-19 | Kirn David | Sell · S · 10b5-1 | 25,927 | $16.42 | $425,651 | Form 4 |
| 2026-08-17 | Bizily Scott | Sell · S · 10b5-1 | 1,635 | $12.20 | $19,947 | Form 4 |
| 2026-08-13 | Bizily Scott | Sell · S · 10b5-1 | 1,635 | $12.00 | $19,620 | Form 4 |
| 2026-08-04 | Kirn David | Sell · S · 10b5-1 | 26,842 | $10.23 | $274,596 | Form 4 |
| 2026-08-03 | Kirn David | Sell · S · 10b5-1 | 12,415 | $10.05 | $124,722 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-18 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
FDMT presents a deeply unfavorable risk/reward profile: despite a solid liquidity buffer (score 85), the fundamental trend is critically weak (score 25) with persistent operating losses, negative cash flows, and no…
The first sentence of the analysis written for FDMT on 2026-09-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $1.7M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $1.7M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 9.39 · operating margin -187% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 91.1% | -381789.2% | -368.5% | -2464.8% | -240.2% | |
| Ebit Margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | |
| Ebitda Margin | -155.5% | -416656.8% | -458.9% | -3311.4% | -378.6% | |
| Operating Profit Margin | -187.2% | -507678.4% | -544.6% | -3516.5% | -395.5% | |
| Pretax Profit Margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | |
| Continuous Operations Profit Margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | |
| Net Profit Margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | |
| Bottom Line Profit Margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | |
| Current Ratio | 9.393 | 14.921 | 15.650 | 14.018 | 15.686 | |
| Quick Ratio | 9.393 | 14.921 | 15.650 | 14.018 | 15.686 | |
| Solvency Ratio | -2.170 | -3.097 | -2.966 | -3.396 | -1.987 | |
| Cash Ratio | 1.370 | 5.123 | 13.145 | 3.328 | 9.365 | |
| Price To Earnings Ratio | -3.099 | -1.869 | -7.853 | -7.119 | -8.919 | |
| Price To Earnings Growth Ratio | 0.165 | -0.121 | 0.454 | -0.265 | -0.556 | |
| Forward Price To Earnings Growth Ratio | 0.165 | -0.121 | 0.454 | -0.265 | -0.556 | |
| Price To Earnings Diluted Ratio | -3.099 | -1.869 | -7.853 | -7.119 | -8.919 | |
| Price To Earnings Diluted Growth Ratio | 0.165 | -0.121 | 0.454 | -0.265 | -0.556 | |
| Price To Book Ratio | 0.859 | 0.588 | 2.575 | 3.106 | 1.907 | |
| Price To Sales Ratio | 5.099 | 8,120.720 | 38.256 | 229.633 | 33.729 | |
| Price To Free Cash Flow Ratio | -3.983 | -2.171 | -10.091 | -7.315 | -7.776 | |
| Price To Operating Cash Flow Ratio | -3.983 | -2.233 | -10.460 | -8.289 | -8.800 | |
| Debt To Assets Ratio | 0.038 | 0.044 | 0.043 | 0.062 | 0.047 | |
| Debt To Equity Ratio | 0.042 | 0.048 | 0.048 | 0.070 | 0.052 | |
| Debt To Capital Ratio | 0.041 | 0.046 | 0.045 | 0.065 | 0.049 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.121 | 1.097 | 1.104 | 1.132 | 1.108 | |
| Working Capital Turnover Ratio | 0.220 | 0.000 | 0.086 | 0.014 | 0.071 | |
| Operating Cash Flow Ratio | -2.480 | -4.617 | -3.999 | -5.510 | -4.231 | |
| Operating Cash Flow Sales Ratio | -1.280 | -3,637.432 | -3.657 | -27.704 | -3.833 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.028 | 1.037 | 1.133 | 1.132 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -5.094 | -5.470 | -5.166 | -5.376 | -4.203 | |
| Capital Expenditure Coverage Ratio | -203.511 | -35.548 | -27.352 | -7.514 | -7.589 | |
| Dividend Paid And Capex Coverage Ratio | -203.511 | -35.548 | -27.352 | -7.514 | -7.589 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.986 | -1.140 | -5.872 | -6.585 | -6.909 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 91.0% | ▲381880.2% | ▲77045.4% |
| Ebit Margin | -164.4% | ▲434614.0% | ▲87687.6% |
| Ebitda Margin | -155.5% | ▲416501.3% | ▲84036.7% |
| Operating Profit Margin | -187.2% | ▲507491.1% | ▲102277.2% |
| Pretax Profit Margin | -164.4% | ▲434614.0% | ▲87687.6% |
| Continuous Operations Profit Margin | -164.4% | ▲434614.0% | ▲87687.6% |
| Net Profit Margin | -164.4% | ▲434614.0% | ▲87687.6% |
| Bottom Line Profit Margin | -164.4% | ▲434614.0% | ▲87687.6% |
| Current Ratio | 9.393 | ▼-5.528 | ▼-4.541 |
| Quick Ratio | 9.393 | ▼-5.528 | ▼-4.541 |
| Solvency Ratio | -2.170 | ▲0.927 | ▲0.553 |
| Cash Ratio | 1.370 | ▼-3.754 | ▼-5.096 |
| Price To Earnings Ratio | -3.099 | ▼-1.230 | ▲2.672 |
| Price To Earnings Growth Ratio | 0.165 | ▲0.285 | ▲0.230 |
| Forward Price To Earnings Growth Ratio | 0.165 | ▲0.285 | ▲0.230 |
| Price To Earnings Diluted Ratio | -3.099 | ▼-1.230 | ▲2.672 |
| Price To Earnings Diluted Growth Ratio | 0.165 | ▲0.285 | ▲0.230 |
| Price To Book Ratio | 0.859 | ▲0.271 | ▼-0.948 |
| Price To Sales Ratio | 5.099 | ▼-8115.621 | ▼-1680.388 |
| Price To Free Cash Flow Ratio | -3.983 | ▼-1.812 | ▲2.284 |
| Price To Operating Cash Flow Ratio | -3.983 | ▼-1.750 | ▲2.770 |
| Debt To Assets Ratio | 0.038 | ▼-0.006 | ▼-0.009 |
| Debt To Equity Ratio | 0.042 | ▼-0.006 | ▼-0.009 |
| Debt To Capital Ratio | 0.041 | ▼-0.005 | ▼-0.009 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.121 | ▲0.023 | ▲0.008 |
| Working Capital Turnover Ratio | 0.220 | ▲0.220 | ▲0.142 |
| Operating Cash Flow Ratio | -2.480 | ▲2.137 | ▲1.688 |
| Operating Cash Flow Sales Ratio | -1.280 | ▲3636.152 | ▲733.501 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.028 | ▼-0.066 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -5.094 | ▲0.375 | ▼-0.032 |
| Capital Expenditure Coverage Ratio | -203.511 | ▼-167.963 | ▼-147.208 |
| Dividend Paid And Capex Coverage Ratio | -203.511 | ▼-167.963 | ▼-147.208 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.986 | ▼-1.846 | ▲1.712 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $434.5M | $300.5M | $792.8M | $718.5M | $608.4M | |
| Enterprise value | $395.6M | $175.7M | $558.3M | $682.3M | $471.9M | |
| EV / Sales | 4.64x | 4749.64x | 26.94x | 218.06x | 26.16x | |
| EV / Op. cash flow | -3.63x | -1.31x | -7.37x | -7.87x | -6.83x | |
| EV / Free cash flow | -3.63x | -1.27x | -7.11x | -6.95x | -6.03x | |
| EV / EBITDA | -2.99x | -1.14x | -5.87x | -6.58x | -6.91x | |
| Net debt / EBITDA | 0.29x | 0.81x | 2.46x | 0.35x | 2.00x | |
| Current ratio | 9.39x | 14.92x | 15.65x | 14.02x | 15.69x | |
| Income quality | 0.78x | 0.84x | 0.75x | 0.81x | 0.97x | |
| Graham net-net | $6 | $7 | $7 | $6 | $8 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $369.1M | $405.8M | $277.6M | $204.8M | $239.9M | |
| Invested capital | $402.2M | $446.4M | $309.3M | $240.1M | $268.9M | |
| Return on assets | -24.7% | -28.7% | -29.7% | -41.1% | -20.2% | |
| Operating ROA | -28.3% | -41.7% | -37.5% | -35.8% | -22.2% | |
| Return on tangible assets | -24.7% | -28.7% | -29.7% | -41.1% | -20.2% | |
| Return on equity | -27.7% | -31.5% | -32.8% | -46.5% | -22.3% | |
| Return on invested capital | -30.2% | -35.0% | -34.8% | -44.2% | -21.1% | |
| Return on capital employed | -30.5% | -35.4% | -35.2% | -44.7% | -21.2% | |
| Earnings yield | -32.2% | -53.5% | -12.7% | -15.0% | -11.7% | |
| Free cash flow yield | -25.1% | -46.1% | -9.9% | -13.7% | -12.9% | |
| Capex / Op. cash flow | -0.5% | -2.8% | -3.7% | -13.3% | -13.2% | |
| Capex / Depreciation | 7.0% | 56.5% | 48.2% | 297.3% | 301.7% | |
| Capex / Sales | 0.6% | 10232.4% | 13.4% | 368.7% | 50.5% | |
| SG&A / Sales | 57.6% | 125889.2% | 176.1% | 1051.7% | 155.3% | |
| R&D / Sales | 229.7% | 381889.2% | 468.5% | 2564.8% | 340.2% | |
| Stock comp / Sales | 25.8% | 70583.8% | 94.9% | 547.2% | 76.5% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 1d | |
| Days payables outstanding | 534d | 11d | 13d | 15d | 28d | |
| Operating cycle | 0d | 0d | 0d | 0d | 1d | |
| Cash conversion cycle | -534d | -11d | -13d | -15d | -27d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 4DMT to Host Investor Day on October 21, 2026 Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.
- 2026-09-29 4D Molecular: Reiterate ''Buy'' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway 4D Molecular Therapeutics remains a ''Buy'' as its gene therapy 4D-150 advances in phase 3 trials for wet AMD and diabetic macular edema [DME]. Topline data from the pivotal 4FRONT-1 and 4FRONT-2 wet AMD studies are expected in Q2 and H2 2027, supporting regulatory filings for both wet AMD. Phase 2b and SPECTRA data show 4D-150 reduces injection burden by up to 87% in wet AMD and 61% in DME, with the potential to disrupt the $14B+ anti-VEGF market.
- 2026-09-28 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The Company also reported 2-year data from the SPECTRA clinical trial.
- 2026-09-24 Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the firm''s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $13.65, for a total transaction of $22,317.75. Following the completion of the sale, the insider owned 8,617 shares in the
- 2026-09-21 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average PT from Brokerages Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have issued a buy recommendation and one
- 2026-09-17 4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript 4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
- 2026-09-14 4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-11 4DMT Announces New Employment Inducement Grants EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company''s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company''s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
- 2026-08-25 4DMT to Participate in Upcoming Investor Conferences EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September:
- 2026-08-25 4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 17.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 974,173 shares of the company''s stock after purchasing an additional 141,582 shares during the quarter.